Publications
Messamore, E. (2017).
The niacin response biomarker as a schizophrenia endophenotype: A status update.
Prostaglandins Leukotrienes and Essential Fatty Acids. doi: 10.1016/j.plefa.2017.06.014.
READMessamore, E., and Yao, J.K. (2016).
Phospholipid, arachidonate and eicosanoid signaling in schizophrenia.
OCL23, D112.
READMessamore, E., Hoffman, W.F., and Yao, J.K. (2010).
Niacin Sensitivity and the Arachidonic Acid Pathway in Schizophrenia.
Schizophrenia Research 122, 248–256.
READMessamore, E. (2003).
The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.
Schizophrenia Research62, 251–258.
READMessamore, E., Warpman, U., Ogane, N., and Giacobini, E. (1993).
Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex.
Neuropharmacology32, 745–750.
READCowburn, R.F., Messamore, E., Li, M.L., Winblad, B., and Sundström, E. (1994).
beta-Amyloid related peptides exert differential effects on [3H]MK-801 binding to rat cortical membranes.
Neuroreport5, 405–408.
READOgane, N., Giacobini, E., and Messamore, E. (1992).
Preferential inhibition of acetylcholinesterase molecular forms in rat brain.
Neurochemical Research. 17, 489–495.
READSherman K.A. and E. Messamore.
Cholinesterase inhibitor therapy: what do animal models tell us?
Prog. Clin. Biol. Res. 317: 1209-1222, 1989.
READMiller, T.M., Poloyac, S.M., Anderson, K.B., Waddell, B.L., Messamore, E., and Yao, J.K. (2017).
A rapid UPLC-MS/MS assay for eicosanoids in human plasma: Application to evaluate niacin responsivity.
Prostaglandins Leukotrienes and Essential Fatty Acids. doi: 10.1016/j.plefa.2017.01.003.
READYao, J.K., Dougherty, G.G., Gautier, C.H., Haas, G.L., Condray, R., Kasckow, J.W., Kisslinger, B.L., Gurklis, J.A., and Messamore, E. (2016).
Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia.
Schizophrenia Bulletin 42, 369–376.
READHansen, T.E., Snyder, K., Messamore, E. and Hoffman, W.F. (2004).
Metabolic side effects of antipsychotic medications: clinical laboratory implications.
Laboratory Medicine35, 625-627.
READMessamore, E., Bogdanovich, N., Schröder, H., and Winblad, B. (1994).
Astrocytes associated with senile plaques possess muscarinic acetylcholine receptors.
Neuroreport5, 1473–1476.
READMessamore, E., Warpman, U., Williams, E., and Giacobini, E. (1993).
Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition.
Neuroscience Letters.158, 205–208.
READWinblad, B., Messamore, E., O’Neill, C., and Cowburn, R. (1993).
Biochemical pathology and treatment strategies in Alzheimer’s disease: emphasis on the cholinergic system.
Acta Neurol. Scand., Suppl. 149, 4–6.
READGiacobini E., D. Linville, E. Messamore, and N. Ogane.
Toward a third generation of cholinesterase inhibitors: pharmacological aspects.
Becker R and E Giacobini (eds) Cholinergic Basis for Alzheimer Therapy. pp. 477-490. Boston: Birkhäuser, 1991.
READSherman K.A. and E. Messamore.
Blood cholinesterase inhibition as a guide to the efficacy of tacrine and physostigmine.
Giacobini, E and R Becker (eds) Current Research in Alzheimer Therapy: Cholinesterase Inhibitors. pp. 73-86. New York: Taylor and Francis, 1988.
READMessamore, E., Almeida, D.M., Jandacek, R.J., and McNamara, R.K. (2017).
Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.
Progress in lipid research. 66, 1–13.
READMessamore, E. (2012).
Niacin subsensitivity is associated with functional impairment in schizophrenia.
Schizophrenia Research137, 180–184.
READMessamore, E. (2003).
Relationship between the niacin skin flush response and essential fatty acids in schizophrenia.
Prostaglandins, Leukotrienes, and Essential Fatty Acids, 69: 413-419, 2003.
READMessamore, E., Ogane, N., and Giacobini, E. (1993).
Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum.
Neuropharmacology32, 291–296.
READNordstedt, C., Näslund, J., Thyberg, J., Messamore, E., Gandy, S.E., and Terenius, L. (1994).
Human neutrophil phagocytic granules contain a truncated soluble form of the Alzheimer beta/A4 amyloid precursor protein (APP).
Journal of Biological Chemistry. 269, 9805–9810.
READWinblad B., E. Messamore, C. O’Neill, and R. Cowburn:
Biochemical pathology and treatment strategies in Alzheimer’s disease: emphasis on the cholinergic system.
Acta Neurologica Scandinavica. Supplementum.149: 4-6, 1993.
Sherman, K.A., and Messamore, E. (1989).
Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us?
Progress in Clinical and Biological Research. 317, 1209–1222.